AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34034929
Drug: CNS-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS-directed therapy comprising four to 11 courses of i.v. methotrexate (5 g/m2) and 10 to 19 intrathecal chemotherapy injections, depending on risk group and CNS status.
Trial: 32020813
Drug: Pre-bronchodilator spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-bronchodilator spirometry
Trial: 32020813
Drug: Post-bronchodilator spirometry
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator spirometry
Trial: 32020813
Drug: Treatment status
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment status
Trial: 36435746
Drug: Providers with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Providers with a reduction in antibiotic prescribing
Trial: 32224082
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) 1 g intravenously preoperatively
Trial: 35130054
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g acetaminophen 4× daily
Trial: 34971331
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation of the rectus femoris and gastrocnemius muscles bilaterally, applied for 60 min, twice a day for up to 10 sessions until postoperative day 5.
Trial: 38283689
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine
Trial: 36951156
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral azacitidine maintenance therapy
Trial: 34751784
Drug: Hip-focused treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip-focused treatment
Trial: 34751784
Drug: Spine-focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spine-focused treatment
Trial: 35182115
Drug: Treatment and
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment and prevention complex
Trial: 33350370
Drug: Azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20 mg/kg single dose)
Trial: 34514614
Drug: Remifentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil plasma target concentration of 0 ng/ml (group R0)
Trial: 34514614
Drug: Remifentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil plasma target concentration of 1 ng/ml (group R1)
Trial: 34514614
Drug: Remifentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil plasma target concentration of 2 ng/ml (group R2)
Trial: 36194619
Drug: Oral Qurs‐e‐Asfar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Qurs‐e‐Asfar (QA) 778 mg twice a day and topical Rogan‐e‐Narjeel (RN)
Trial: 36194619
Drug: Oral Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Itraconazole (100 mg/day) and topical Terbinafine hydrochloride (1%)
Trial: 34710784
Drug: Sildenafil tablets
RxNorm normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil tablets
Trial: 33509742
Drug: Curcumin mucoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin mucoadhesive patches
Trial: 34789394
Drug: Cabazitaxel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (25 mg/m2 every 3 wk × 4 cycles)
Trial: 34789394
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 every 3 wk × 4 cycles)
Trial: 35098012
Drug: Infertility treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infertility treatment training program (Control)
Trial: 35617841
Drug: Twice-daily hypertonic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily hypertonic saline irrigation for 6 weeks
Trial: 35617841
Drug: Twice-daily saline/xylitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily saline/xylitol irrigation for 6 weeks
Trial: 34516169
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol (target BAC = .08%)
Trial: 32838679
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First with Assertive Community Treatment (ACT)
Trial: 33705169
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (DESTRESS-WV and phone monitoring)
Trial: 36268543
Drug: Internet-based writing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based writing intervention (6 weeks, six structured writing assignments based on cognitive behavioral therapy)
Trial: 34825283
Drug: Preoperative prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative prophylactic antibiotics
Trial: 34825283
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no preoperative prophylactic antibiotics)
Trial: 32862425
Drug: Supervised group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised group exercise (12 weeks, twice weekly)
Trial: 36808268
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg ODT
Trial: 36891452
Drug: PECs II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PECs II block with 25 ml of 0.25% bupivacaine
Trial: 34288696
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of FOLFIRINOX followed by leucovorin plus fluorouracil maintenance treatment (arm B)
Trial: 34288696
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment alternating gemcitabine and fluorouracil, leucovorin, and irinotecan every 2 months (arm C)
Trial: 35076797
Drug: PrEP taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP taken by daily pill
Trial: 35076797
Drug: PrEP by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP by injection
Trial: 35076797
Drug: PrEP by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP by pill
Trial: 35076797
Drug: Other PrEP
RxNorm normalized name: other preparations, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other PrEP modalities (event-based pill, anal suppository, gel, condoms)
Trial: 32246765
Drug: GM-CSF (intrauterine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (intrauterine infusion)
Trial: 32246765
Drug: Control (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (gel without GM-CSF)
Trial: 32827307
Drug: Prophylactic nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic nimodipine treatment
Trial: 34563097
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant epidermal growth factor (h‐EGF) in 2% carboxymethyl cellulose gel
Trial: 34563097
Drug: 2% carboxymethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% carboxymethyl cellulose gel (control)
Trial: 34654942
Drug: GI-0.025 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI-0.025 mL
Trial: 34654942
Drug: GII-0.05 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GII-0.05 mL
Trial: 34654942
Drug: GIII-0.10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIII-0.10 mL
Trial: 32243582
Drug: Paroxetine (5-HT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (5-HT reuptake inhibitor)
Trial: 2011535125
Drug: Pedimed cream
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pedimed cream
Trial: 34735098
Drug: Bupropion (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (150-300 mg/d)
Trial: 32573927
Drug: Exenatide ER
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide ER 2 mcg weekly
Trial: 35490395
Drug: Baricitinib (BARI)
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib (BARI) 2-4 mg
Trial: 35490395
Drug: Baricitinib (BARI)
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib (BARI) 2 mg
Trial: 35490395
Drug: Baricitinib (BARI)
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib (BARI) 4 mg
Trial: 34118259
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with morphine 1 mcg.kg-1 (n=15)
Trial: 35977762
Drug: Oral pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pills
Trial: 34214736
Drug: Fractionated HPC
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated HPC infusion (4 × 10^6 CD34+ cells/kg on day 0, remaining cells infused on days 2, 4, and 6)
Trial: 34214736
Drug: Bulk HPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulk HPC infusion (7 × 10^6 CD34+ cells/kg)
Trial: 34214736
Drug: Fractionated HPC
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated HPC infusion
Trial: 34214736
Drug: Bulk HPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulk HPC infusion
Trial: 35135986
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 800 mg daily
Trial: 35642697
Drug: Core stability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core stability exercise program (30 min, in addition to standard physical therapy program)
Trial: 35642697
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy program (1 h per session, three times weekly)
Trial: 35935235
Drug: LTBI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTBI treatment (specific regimen not detailed)
Trial: 35549538
Drug: Escitalopram (8-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (8-week treatment)
Trial: 34980541
Drug: Chemotherapy (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (arm A)
Trial: 36008895
Drug: Allopurinol orally,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol orally, 100 mg/time, tid, for 12 weeks
Trial: 35339323
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) with traditional rehabilitation
Trial: 36229155
Drug: Healthy Habits
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Habits Triple P - Oral health (web-based parenting intervention)
Trial: 36229155
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral health-related information published by Australian oral health agencies)
Trial: 32228315
Drug: Pazopanib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (600 mg orally daily in 2 divided doses, 400 and 200 mg) and cyclophosphamide (50 mg orally daily for 21 days every 28 days)
Trial: 34922567
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure plus rescue medication (RM)
Trial: 32764634
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic lozenges containing Streptococcus salivarius M18
Trial: 33207935
Drug: Prazosin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (16 mg/day, with a 2-week titration)
Trial: 35148195
Drug: YES-10 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YES-10 (200 mg, 2 capsules daily for 4 weeks)
Trial: 35148195
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules daily for 4 weeks)
Trial: 32009286
Drug: Newer glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer glucose-lowering medications (sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists)
Trial: 35970013
Drug: Multiagent induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent induction chemotherapy (ICT; nab-paclitaxel/gemcitabine alone or nab-paclitaxel/gemcitabine followed by FOLFIRINOX) for 16 weeks
Trial: 35970013
Drug: Multiagent induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent induction chemotherapy (ICT) with robust CA 19-9 response (decrease to ≤50 U/ml)
Trial: 35970013
Drug: CA 19-9
RxNorm normalized name: CA-19-9 antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 19-9 decrease to ≤61 U/ml as optimal cut-off
Trial: 38251533
Drug: Riociguat (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (up to 2.5 mg three times daily)
Trial: 33779938
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg once daily
Trial: 34710363
Drug: Supervised primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised primaquine treatment (0.5 mg/kg per day for 14 days, supervised on alternate days)
Trial: 34710363
Drug: Unsupervised primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised primaquine treatment (0.5 mg/kg per day for 14 days, unsupervised)
Trial: 34710363
Drug: Supervised primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised primaquine treatment
Trial: 34710363
Drug: Unsupervised primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised primaquine treatment
Trial: 36196180
Drug: Low-dose hydroxyurea
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydroxyurea
Trial: 36196180
Drug: Moderate-dose hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose hydroxyurea
Trial: 36196180
Drug: State-supported stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State-supported stroke screening service and treatment
Trial: 36053298
Drug: Oral OXT
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral OXT (24IU)
Trial: 33356529
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg/day) plus androgen deprivation therapy
Trial: 37945297
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric derisomaltose
Trial: 33361029
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg every 12 hours)
Trial: 33361029
Drug: Prednisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (20 mg once daily for 2 weeks)
Trial: 32514820
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g or 30 g 10% trehalose solution administered weekly via IV
Trial: 37878483
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (1 g/day)
Trial: 35172587
Drug: Xevinapant monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xevinapant monotherapy
Trial: 34226496
Drug: Psychotropic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medications associated with weight gain
Trial: 34226496
Drug: Psychotropic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medications with high risk of weight gain
Trial: 32618247
Drug: Dihydroartemisinin-Piperaquine (DHAP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-Piperaquine (DHAP) administered in four rounds of mass drug administration (MDA)
Trial: 32618247
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care without any mass treatment
Trial: 34405423
Drug: MultiPole Pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MultiPole Pacing (MPP) therapy
Trial: 32215583
Drug: SRT plus
RxNorm normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT plus high-dose nonsteroidal antiandrogen (bicalutamide, 150 mg/d) for 2 years
Trial: 36329722
Drug: Aframomum melegueta
RxNorm normalized name: Aframomum angustifolium seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aframomum melegueta seed extract (AfperFit) 250 mg, twice daily for 12 weeks
Trial: 33037808
Drug: Xylitol–malic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol–malic acid tablets (as a supplement to omeprazole 40 mg/day)
Trial: 35118156
Drug: Autologous adipose-derived
RxNorm normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous adipose-derived stromal vascular fractions (SVF) injections
Trial: 34332547
Drug: Cerebral oxygenation
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral oxygenation monitoring treatment
Trial: 34332547
Drug: Monitoring and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring and treatment as usual
Trial: 33876259
Drug: Ibuprofen before
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen before exercise (IP)
Trial: 33876259
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before and ibuprofen after exercise (PI)
Trial: 32545223
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with toluidine blue O and LED light, applied at baseline and 3-months in addition to non-surgical periodontal treatment
Trial: 32571859
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise programme (12-week tailored programme with weekly telephone calls for exercise progression)
Trial: 34127645
Drug: Jackfruit365™ green
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jackfruit365™ green jackfruit flour 30 g/day (Group A)
Trial: 33451962
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (20 mg bolus followed by 5 μg/kg/min infusion)
Trial: 33451962
Drug: Narcotic-only control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic-only control (100 μg fentanyl with additional fentanyl and 0.3 mg hydromorphone)
Trial: 32160948
Drug: RV3-BB rotavirus
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB rotavirus vaccine (neonatal schedule, first dose at 0-5 days of age)
Trial: 32160948
Drug: RV3-BB rotavirus
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB rotavirus vaccine (infant schedule, first dose at 8 weeks of age)
Trial: 32823413
Drug: Anti-VEGF monotherapy
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF monotherapy
Trial: 37716893
Drug: Treatment-as-usual (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (control condition)
Trial: 33735670
Drug: Inhaled levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levosimendan (LS)
Trial: 33735670
Drug: Intravenous levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levosimendan (LS)
Trial: 32569102
Drug: Daily 30-minute
RxNorm normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily 30-minute massage for 7 consecutive days
Trial: 32569102
Drug: Daily 30-minute
RxNorm normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily 30-minute restriction of non-essential caregiving (Quiet Time) for 7 consecutive days
Trial: 34973853
Drug: burn+glutamine (B+G)
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: burn+glutamine (B+G)
Trial: 34187394
Drug: Nifedipine/indomethacin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine/indomethacin combination therapy
Trial: 33527395
Drug: Eperisone 50
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eperisone 50 mg (Murex®)
Trial: 616886746
Drug: Chinese medicine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine-based nursing care